Boston Scientific (BSX) Reports In-Line Q1 EPS

Go back to Boston Scientific (BSX) Reports In-Line Q1 EPS

Boston Scientific (BSX) PT Raised to $21 at Leerink Partners Following Q1

April 29, 2015 8:57 AM EDT

Leerink Partners analyst Danielle Antalffy reiterated an Outperform rating and boosted its price target Boston Scientific (NYSE: BSX) price target of $21.00 (from $18.00) following Q1 results and solid 2015 outlook.

Antalffy commented, "Over the last two years, BSX's turnaround story has steadily played out, with new management delivering... More